养心定悸胶囊联合多巴丝肼治疗帕金森病的临床研究

目的 探讨养心定悸胶囊联合多巴丝肼片对帕金森病患者的临床疗效。方法 选择定州市人民医院2017年8月-2019年8月收治的帕金森病患者60例作为研究对象，采用随机原则将患者分为观察组与对照组，每组各30例。对照组采用多巴丝肼片治疗，初始剂量0.25 g/次，3次/d，1周后逐渐根据病情调整用量，直到达到适合患者的治疗量为止，最高剂量不超过1 g/d，分3~4次服用。观察组在对照组治疗的基础上联合养心定悸胶囊，3 g/次，2次/d。两组治疗时间均为12周。观察两组患者的临床疗效，同时比较两组治疗前后的帕金森评定量表（UPDRS）、自主神经症状量表（SCOPT-AUT）、帕金森生活质量问卷（PDQ-39）评分及神经递质水平。结果 治疗后，观察组患者总有效率90.00%，显著高于对照组66.67%（P<0.05）。治疗后，两组UPDRS、SCOPT-AUT、PDQ-39评分均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后，观察组各评分显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清血清5-羟色胺（5-HT）、去甲肾上腺素（NE）、多巴胺（DA）水平比较显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后，观察组5-HT、NE、DA水平显著高于对照组，两组比较差异具有统计学意义（P<0.05）。结论 养心定悸胶囊联合多巴丝肼片治疗帕金森病效果显著，能够显著缓解症状，改善自主神经功能和神经递质水平，有利于患者生活质量的提高，且具有较好的安全性。

Clinical study of Yangxin Dingji Capsules combined with levodopa and benserazide in treatment of Parkinson's disease

Objective To investigate the effect of Yangxin Dingji Capsules combined with Levodopa and Benserazide Hydrochloride Tablets on patients with Parkinson''s disease. Methods Patients (60 cases) with Parkinson''s disease in Dingzhou City People''s Hospital from August 2017 to August 2019 were selected as the study objects, and were randomly divided into observation group and control group, with 30 cases in each group. The control group was treated with Levodopa and Benserazide Hydrochloride Tablets, the initial dose was 0.25 g/time, three times daily, and the dosage was gradually adjusted according to the condition after 1 week, until the appropriate amount of treatment was reached, the maximum dose did not exceed 1 g/d for 3-4 times. The observation group was treated with Yangxin Dingji Capsules on the basis of control group, 3 g/time, twice daily. Both groups were treated for 12 weeks. The clinical efficacy of two groups was observed, and the scores of UPDRS, SCOPT-AUT, PDQ-39, and neurotransmitter levels before and after treatment were compared. Results After treatment, the total effective rate of the observation group was 90.00%, which was higher than 66.67% of the control group (P<0.05). After treatment, the scores of UPDRS, SCOPTAUT, and PDQ-39 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, these scores in the observation group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the serum levels of 5-HT, NE, and DA in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the levels of 5-HT, NE, and DA in the observation were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Yangxin Dingji Capsules combined with Levodopa and Benserazide Hydrochloride Tablets has a remarkable effect on the treatment of Parkinson''s disease, which can significantly relieve symptoms, improve autonomic nerve function and neurotransmitter level, and is conducive to the improvement of patients'' quality of life, and has a good safety.